focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options - Director/PDMR Shareholding

14 Dec 2022 17:08

RNS Number : 7510J
Evgen Pharma PLC
14 December 2022
 

Evgen Pharma plc

("Evgen" or the "Company")

 

Grant of Options

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company developing sulforaphane-based medicines announces that, on 14 December 2022, certain employees and directors of the Company, including the following Persons Discharging Managerial Responsibility ("PDMR"), were granted nil cost options (the "Options") over a total of 11,122,199 ordinary shares of 0.25 pence each in the Company ("Ordinary Shares"), exercisable, subject to the Options vesting, for a period of up to 10 years from the date of grant and governed by the rules of the Evgen Pharma plc Long Term Incentive Plan ("LTIP").

 

PDMR

Position

Current Ordinary Shares held

Current Options held

New options granted

% of issued share capital including this award

Dr Huw Jones

CEO

62,500

4,648,890

4,410,727

3.3%

Richard Moulson

CFO

45,454

889,728

1,460,855

 

0.9%

 

The Options will vest on the third anniversary of grant based on performance against challenging

strategic corporate objectives over three years (40%), share price growth (30%) and on an elapsed time basis at 3 years (30%).

 

Following this award there are 21,361,574 options in issue, representing 7.8% of the Company's issued share capital.

 

Enquiries:

Evgen Pharma plcDr Huw Jones, CEO Richard Moulson, CFO 

+44 1625 466591

FinnCap (Nominated Advisor and Broker) Geoff Nash / Teddy Whiley (Corporate Finance)Alice Lane/Nigel Birks (ECM)

+44 20 7220 0500

Instinctif Partners

Melanie Toyne-Sewell / Rozi Morris / Agnes Stephens / Adam Loudon

+44 207 457 2020Evgen@Instinctif.co

 

 

 

The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "UK MAR") which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. The information is disclosed in accordance with the Company's obligations under Article 17 of the UK MAR.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Huw Jones

2

Reason for the notification

a)

Position/status

CEO

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma Plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over Ordinary Shares of 0.25 pence each

 GB00BSVYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

4410727

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 As above

 

 

f)

Date of the transaction

14 December 2022

g)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Richard Moulson

2

Reason for the notification

a)

Position/status

CFO

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Evgen Pharma Plc

b)

Legal Entity Identifier

213800NO3E6TSTQO8K20

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Options over Ordinary Shares of 0.25 pence each

 GB00BSVYN304

 

b)

Nature of the transaction

Grant of options

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

nil

1460855

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 As above

 

 

f)

Date of the transaction

14 December 2022

g)

Place of the transaction

London Stock Exchange, AIM

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUSRBRUSUUAAA
Date   Source Headline
10th Oct 202211:05 amRNSSecond Price Monitoring Extn
10th Oct 202211:00 amRNSPrice Monitoring Extension
10th Oct 20227:00 amRNSSFX-01 licensing deal for up to $160.5m
29th Sep 20227:00 amRNSRegulatory approval for healthy volunteer study
22nd Jul 20227:00 amRNSResult of AGM
14th Jul 202212:43 pmRNSInvestor Presentation
6th Jul 202212:25 pmRNSNotice of AGM
13th Jun 20227:00 amRNSCollaboration with University of Michigan
8th Jun 20227:00 amRNSFull Year Results
7th Jun 20227:00 amRNSNotice of Results
25th May 20227:00 amRNSCollaboration with Università Sapienza di Roma
29th Apr 20222:39 pmRNSHolding(s) in Company
15th Mar 20222:05 pmRNSSecond Price Monitoring Extn
15th Mar 20222:00 pmRNSPrice Monitoring Extension
7th Mar 20227:00 amRNSManchester Breast Centre collaboration expanded
18th Jan 20227:00 amRNSOption over new sulforaphane analogues
11th Jan 20227:00 amRNSProgress with UK and US regulators for 2022 trials
30th Dec 202111:35 amRNSHolding(s) in Company
8th Dec 20212:08 pmRNSGrant of Options
7th Dec 20217:00 amRNSHalf-year Report
23rd Nov 20217:00 amRNSNotice of Results
10th Nov 20217:00 amRNSPublication of data on SFX-01 in glioblastoma
19th Oct 20212:39 pmRNSHolding(s) in Company
20th Sep 20217:00 amRNSPublication of data in glioblastoma cells
2nd Sep 20212:32 pmRNSHolding(s) in Company
2nd Sep 20212:06 pmRNSSecond Price Monitoring Extn
2nd Sep 20212:00 pmRNSPrice Monitoring Extension
2nd Sep 202111:05 amRNSSecond Price Monitoring Extn
2nd Sep 202111:01 amRNSGlioma Orphan Drug designation granted by FDA
2nd Sep 202111:00 amRNSPrice Monitoring Extension
25th Aug 20214:42 pmRNSHolding(s) in Company
24th Aug 20214:41 pmRNSSecond Price Monitoring Extn
24th Aug 20214:36 pmRNSPrice Monitoring Extension
9th Aug 20215:06 pmRNSHolding(s) in Company
20th Jul 202111:57 amRNSHolding(s) in Company
16th Jul 20211:50 pmRNSHolding(s) in Company
14th Jul 202110:23 amRNSHolding(s) in Company
13th Jul 20215:02 pmRNSResult of AGM and Business Update
13th Jul 20213:55 pmRNSHolding(s) in Company
13th Jul 20217:00 amRNSEarly data for SFX-01 in leukaemia cell lines
13th Jul 20217:00 amRNSGlioma Orphan Drug application submitted to US FDA
9th Jul 202111:05 amRNSSecond Price Monitoring Extn
9th Jul 202111:00 amRNSPrice Monitoring Extension
9th Jul 20217:00 amRNSInterim Safety and Futility Analysis - STAR trial
18th Jun 20217:00 amRNSPosting of Annual Report and Notice of AGM
15th Jun 20217:00 amRNSFinal Results
14th Jun 20217:00 amRNSProgress on metastatic breast cancer programme
14th Jun 20217:00 amRNSProgress with Glioma/Glioblastoma programme
26th Apr 20217:00 amRNSAppointment of Chief Medical Officer
7th Apr 20217:00 amRNSPublication on sulforaphane in COVID-19

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.